/NXTCL.ST
NXTCL.ST Stock - NextCell Pharma AB
Healthcare|BiotechnologySTO
$0.70-0.57%
$0.00 (-0.57%) • Dec 23
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.77
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NXTCL.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.69 – $0.70
TARGET (TP)$0.80
STOP LOSS$0.64
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.26
52W High$3.84
52W Low$0.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $10.94M | $10.66M | $10.11M | $5.59M | $3.91M |
| Gross Profit | $-35,871,789 | $-4,558,208 | $-884,834 | $-22,260,709 | $-14,527,509 |
| Gross Margin | -328.0% | -42.7% | -8.7% | -398.3% | -371.4% |
| Operating Income | $-35,871,789 | $-43,172,120 | $-41,002,139 | $-35,023,884 | $-24,821,021 |
| Net Income | $-35,143,091 | $-41,959,818 | $-39,811,631 | $-34,084,746 | $-24,564,328 |
| Net Margin | -321.3% | -393.4% | -393.6% | -609.9% | -627.9% |
| EPS | $-0.46 | $-0.57 | $-0.58 | $-0.51 | $-0.41 |
Company Overview
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NXTCL.STBeat Rate
0%
Last 1 quarters
Avg Surprise
-0.4%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q4 25
-0.4%
$-0.10vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 30, 2025 | $-0.10 | $-0.10 | -0.4% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | — | $-0.11 | — | — |
Q4 2024 | Nov 30, 2024 | — | $-0.11 | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.22 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.13 | — | — |
Q1 2024 | Feb 29, 2024 | — | $-0.15 | — | — |
Q4 2023 | Nov 30, 2023 | — | $-0.14 | — | — |
Q3 2023 | Aug 31, 2023 | — | $-0.12 | — | — |
Q2 2023 | May 31, 2023 | — | $-0.16 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.16 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-0.13 | — | — |
Q3 2022 | Aug 31, 2022 | — | $-0.12 | — | — |
Q2 2022 | May 31, 2022 | — | $-0.13 | — | — |
Q1 2022 | Feb 28, 2022 | — | $-0.15 | — | — |
Q1 2022 | Jan 28, 2022 | — | $-0.09 | — | — |
Q4 2021 | Oct 29, 2021 | — | $-0.09 | — | — |
Q3 2021 | Aug 31, 2021 | — | $-0.07 | — | — |
Q1 2021 | Feb 28, 2021 | — | $-0.14 | — | — |
Q4 2020 | Nov 30, 2020 | — | $-0.12 | — | — |
Q3 2020 | Aug 31, 2020 | — | $-0.11 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NXTCL.ST
What is NXTCL.ST's current stock price?
NextCell Pharma AB (NXTCL.ST) is currently trading at $0.70 per share. The stock has moved -0.57% today.
What is the analyst price target for NXTCL.ST?
No analyst price targets are currently available for this stock.
What sector is NextCell Pharma AB in?
NextCell Pharma AB operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is NXTCL.ST's market cap?
NextCell Pharma AB has a market capitalization of $0.08 billion, making it a small-cap company.
Does NXTCL.ST pay dividends?
No, NextCell Pharma AB does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
BIOSGN.ST
Biosergen AB
$42.60
Mkt Cap: $0.1B
BIOVIC-B.ST
Biovica International AB (publ)
$0.34
Mkt Cap: $0.1B
CMOTEC-B.ST
Scandinavian ChemoTech AB (publ)
$4.79
Mkt Cap: $0.1B
ICO.ST
Iconovo AB (publ)
$1.14
Mkt Cap: $0.1B
IMMNOV.ST
Immunovia AB (publ)
$0.23
Mkt Cap: $0.1B
NICA.ST
Nanologica AB (publ)
$0.71
Mkt Cap: $0.1B
PILA.ST
Pila Pharma AB (publ)
$2.20
Mkt Cap: $0.1B
SPAGO.ST
Spago Nanomedical AB (publ)
$0.10
Mkt Cap: $0.0B
SPRINT.ST
Sprint Bioscience AB (publ)
$1.45
Mkt Cap: $0.2B
Explore stocks similar to NXTCL.ST for comparison